



Corrigendum to “Amyloid beta modulators and neuroprotection in Alzheimer’s disease: a critical appraisal” [Drug Discov. Today 22 (February (2)) (2017) 223–233]

Chandra Sekhar Kuruva¹ and P. Hemachandra Reddy^{1,2,3,4,5,6}, hemachandra.reddy@ttuhsc.edu



¹ Garrison Institute on Aging, Texas Tech University Health Sciences Center, 3601 4th Street, MS 9424, Lubbock, TX 79430, USA

² Department of Cell Biology & Biochemistry, Texas Tech University Health Sciences Center, 3601 4th Street, MS 9424, Lubbock, TX 79430, USA

³ Department of Neuroscience & Pharmacology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 9424, Lubbock, TX 79430, USA

⁴ Department of Neurology, Texas Tech University Health Sciences Center, 3601 4th Street, MS 9424, Lubbock, TX 79430, USA

⁵ Department of Speech, Language and Hearing Sciences, Texas Tech University Health Sciences Center, 3601 4th Street, MS 9424, Lubbock, TX 79430, USA

⁶ Garrison Institute on Aging, South West Campus, Texas Tech University Health Sciences Center, 6630 S. Quaker Ste. E, MS 7495, Lubbock, TX 79413, USA

The authors regret

The legend currently associated with Fig. 3 should be with Fig. 2;

The legend currently associated with Fig. 4 should be with Fig. 3;

The legend currently associated with Fig. 2 should be with Fig. 4.

The authors would like to apologise for any inconvenience caused.

DOI of original article: [10.1016/j.drudis.2016.10.010](https://doi.org/10.1016/j.drudis.2016.10.010)

Corresponding author: Reddy, P.H. (hemachandra.reddy@ttuhsc.edu)